Literature DB >> 33209495

Prognostic significance of controlling nutritional status score-based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation.

Yi Yang1, Feng Ye2, Yujing Xin1, Yanan Wang1, Xiao Li1, Duiping Feng3, Yi Chen1,3, Xiang Zhou1.   

Abstract

BACKGROUND: Radiofrequency ablation (RFA) is a curative therapy for hepatocellular carcinoma (HCC) within Milan criteria. This study was conducted to evaluate the association between controlling nutritional status (CONUT) score and oncological outcomes in HCC patients within Milan criteria after RFA. Nomograms were constructed for the prediction of prognosis.
METHODS: The study included 403 HCC patients within Milan criteria who underwent RFA at National Cancer Center and the First Hospital of Shanxi Medical University from January 2010 to December 2014. Oncological outcomes included disease-free survival (DFS) and overall survival (OS). The clinical variables were assessed by univariate and multivariate Cox regression analyses. C-index, time-dependent receiver operating characteristic (t-ROC) curve (t-AUC) and calibration plots were used to evaluate discrimination and calibration of the nomograms.
RESULTS: Patients were divided into CONUT ≤4 and ≥5 groups. The common prognostic factors affecting DFS and OS were number of lesions, tumor differentiation, and CONUT score. Age and total bilirubin (TBIL) were prognostic factors for OS only. Both DFS and OS rates in CONUT ≤4 group were significantly higher than those in CONUT ≥5 group (P=0.033, P<0.001). Two well-discriminated and calibrated nomograms were constructed to predict the probability of 1-, 2-, and 3-year DFS and 1-, 2-, 3-, 5-year OS with C-indexes of 0.798 and 0.757, respectively.
CONCLUSIONS: CONUT score is an independent prognostic factor for HCC after RFA treatment and a reliable indicator for nutritional interventions. Higher CONUT scores were associated with poor oncological outcomes. Nomograms based on CONUT score could efficiently predict DFS and OS for HCC patients within Milan criteria after RFA. 2020 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); controlling nutritional status (CONUT); nomogram; radiofrequency ablation (RFA)

Year:  2020        PMID: 33209495      PMCID: PMC7657839          DOI: 10.21037/jgo-20-225

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  36 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

2.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cell       Date:  2019-01-24       Impact factor: 41.582

Review 3.  Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.

Authors:  Jean-Charles Nault; Olivier Sutter; Pierre Nahon; Nathalie Ganne-Carrié; Olivier Séror
Journal:  J Hepatol       Date:  2017-10-13       Impact factor: 25.083

4.  Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study.

Authors:  Norifumi Harimoto; Tomoharu Yoshizumi; Shoichi Inokuchi; Shinji Itoh; Eisuke Adachi; Yasuharu Ikeda; Hideaki Uchiyama; Tohru Utsunomiya; Kiyoshi Kajiyama; Koichi Kimura; Fumiaki Kishihara; Keishi Sugimachi; Eiji Tsujita; Mizuki Ninomiya; Kengo Fukuzawa; Takashi Maeda; Ken Shirabe; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2018-07-26       Impact factor: 5.344

5.  Preoperative Controlling Nutritional Status (CONUT) Score for Assessment of Prognosis Following Hepatectomy for Hepatocellular Carcinoma.

Authors:  Kosei Takagi; Takahito Yagi; Yuzo Umeda; Susumu Shinoura; Ryuichi Yoshida; Daisuke Nobuoka; Takashi Kuise; Hiroyuki Araki; Toshiyoshi Fujiwara
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

Review 6.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

7.  Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation.

Authors:  Wei-Yu Kao; Chien-Wei Su; Yi-You Chiou; Nai-Chi Chiu; Chien-An Liu; Kuan-Chieh Fang; Teh-Ia Huo; Yi-Hsiang Huang; Chun-Chao Chang; Ming-Chih Hou; Han-Chieh Lin; Jaw-Ching Wu
Journal:  Radiology       Date:  2017-05-30       Impact factor: 11.105

8.  Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.

Authors:  Gisèle N'Kontchou; Amel Mahamoudi; Mounir Aout; Nathalie Ganne-Carrié; Véronique Grando; Emmanuelle Coderc; Eric Vicaut; Jean Claude Trinchet; Nicolas Sellier; Michel Beaugrand; Olivier Seror
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

Review 9.  Tumour evolution in hepatocellular carcinoma.

Authors:  Amanda J Craig; Johann von Felden; Teresa Garcia-Lezana; Samantha Sarcognato; Augusto Villanueva
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-02       Impact factor: 46.802

Review 10.  Serum cholesterol and cancer risk: an epidemiologic perspective.

Authors:  S B Kritchevsky; D Kritchevsky
Journal:  Annu Rev Nutr       Date:  1992       Impact factor: 11.848

View more
  5 in total

1.  Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.

Authors:  Xiaofeng Chen; Wei Li; Xiaofeng Wu; Fengjiao Zhao; Deqiang Wang; Hao Wu; Yanhong Gu; Xiao Li; Xiaofeng Qian; Jun Hu; Changxian Li; Yongxiang Xia; Jianhua Rao; Xinzheng Dai; Qianwen Shao; Jie Tang; Xiangcheng Li; Yongqian Shu
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

2.  Nutritional Risk Index Predicts Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy.

Authors:  Li Chen; Yihang Qi; Xiangyi Kong; Zhaohui Su; Zhongzhao Wang; Xiangyu Wang; Yaying Du; Yi Fang; Xingrui Li; Jing Wang
Journal:  Front Nutr       Date:  2022-01-13

3.  Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score.

Authors:  Yongjiang Li; Yangxun Pan; Ximeng Lin; Jingyu Hou; Zili Hu; Li Xu; Zhongguo Zhou; Yaojun Zhang; Minshan Chen; Dandan Hu
Journal:  Front Pharmacol       Date:  2022-02-08       Impact factor: 5.810

4.  Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?

Authors:  Lukas Müller; Felix Hahn; Aline Mähringer-Kunz; Fabian Stoehr; Simon J Gairing; Friedrich Foerster; Arndt Weinmann; Peter R Galle; Jens Mittler; Daniel Pinto Dos Santos; Michael B Pitton; Christoph Düber; Roman Kloeckner
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

5.  Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study.

Authors:  Yi Yang; Yanzhao Zhou; Xinyuan Zhang; Yujing Xin; Yi Chen; Qingsheng Fan; Xiao Li; Xi Wei; Qiang Li; Xiang Zhou; Jinxue Zhou
Journal:  J Hepatocell Carcinoma       Date:  2021-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.